Initiation of the Phase 3 study for the second long-acting injectable antipsychotic using MedinCell’s technology (program mdc-TJK)
January 24, 2023
January 24, 2023
MedinCell announces the initiation of coverage of its stock by TPICAP Midcap
January 5, 2023
January 5, 2023
MedinCell announces positive results for the SAIVE clinical study in prevention of Covid-19 infection in a contact-based population
January 5, 2023
January 5, 2023
Publication of the 2023 financial calendar
January 3, 2023
January 3, 2023
MedinCell publishes its financial results for the first semester of 2022-2023
December 6, 2022
December 6, 2022
Additional US$ 4 million received for next development steps of MedinCell’s 6-month active injectable bioresorbable subcutaneous contraceptive
November 30, 2022
November 30, 2022
Details of the financing agreement signed by MedinCell and the European Investment Bank (EIB)
November 23, 2022
November 23, 2022
France : EIB and MedinCell sign a new €40 million loan agreement to support development of innovative treatments
November 23, 2022
November 23, 2022
MedinCell announces its participation in the Jefferies London Healthcare Conference 2022, 15-17 November in London
November 8, 2022
November 8, 2022
MedinCell announces the initiation of Phase 3 study of F14 (mdc-CWM), a therapeutic first-in-class that aims to provide weeks of localized pain relief after Total Knee Replacement
